The proportion of patients without any prostate cancer associated utilization was significantly lower for men cared for by high PSA rate PCPs compared to those cared for by low PSA rate PCPs (OR = 0.27, 95 % CI: 0.26-0.29). This evidence concerns the gene KLK3 and Familial prostate cancer.